1. Inicio
  2. Publicaciones
  3. Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients.

Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Garcia-Martínez I
  • Borràs N
  • Martorell M
  • Parra R
  • Altisent C
  • Ramírez L
  • Álvarez-Román MT
  • Nuñez R
  • Corrales I
  • Alonso S
  • Vidal F

Grupos

Abstract

The pharmacokinetic (PK) response of severe hemophilia A (HA) patients to infused factor VIII (FVIII) shows substantial variability. Several environmental and genetic factors are associated with changes in FVIII plasma levels and infused FVIII PK. Based on the hypothesis that factors influencing endogenous FVIII can affect FVIII PK, the contribution of single-nucleotide variants (SNVs) in candidate genes was investigated in 51 severe HA patients. The effects of blood group, F8 variant type, von Willebrand factor antigen and activity levels, age, and weight were also explored. The myPKFiT device was used to estimate individual PK parameters, and SNVs and clinically reportable F8 variants were simultaneously analyzed in an Illumina MiSeq instrument, using the microfluidics-based Fluidigm Access Array system. The contribution of SNVs to FVIII half-life and clearance was addressed by robust regression modeling, taking into account other modulators. In line with previous studies, we provide robust evidence that age, body weight, and blood group, as well as SNVs in ABO and CLEC4M , participate in the variability of FVIII PK in HA patients. Main results: each copy of the rs7853989 ( ABO ) allele increases FVIII half-life by 1.4 hours ( p = 0.0131) and decreases clearance by 0.5 mL/h/kg ( p = 5.57E-03), whereas each additional rs868875 ( CLEC4M ) allele reduces FVIII half-life by 1.1 hours ( p = 2.90E-05) and increases clearance by 0.3 mL/h/kg ( p = 1.01E-03). These results contribute to advancing efforts to improve FVIII replacement therapies by adjusting to each patient's PK profile based on pharmacogenomic data. This personalized medicine will decrease the burden of treatment and maximize the benefits obtained.

Datos de la publicación

ISSN/ISSNe:
0340-6245, 2567-689X

THROMBOSIS AND HAEMOSTASIS  SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN

Tipo:
Article
Páginas:
1395-1406
PubMed:
32726853
Factor de Impacto:
1,970 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 11

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • hemophilia A; single-nucleotide variants; pharmacokinetic; molecular diagnosis; pharmacogenetics

Proyectos y Estudios Clínicos

COMPREHENSIVE, INTEGRATIVE AND GENOMIC APPROACH TO THE UNDERSTANDING AND TREATMENT OF CANCER AND LEUKEMIA.

Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO

PIE13/00046 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014

EVALUACIÓN DE EFICACIA Y TOXICIDAD DE LA TERAPIA ANTIFÚNGICA CON VORICONAZOL EN BASE A ESTUDIOS FARMACOGENÉTICOS Y ANÁLISIS FARMACOCINÉTICOS-FARMACODINÁMICOS.

Investigador Principal: VIRGINIA BOSÓ RIBELLES

MJL-VOR-2016-01 . 2018

ESTUDIO DE FACTORES GENÉTICOS Y BIOLÓGICOS QUE INFLUENCIAN LA FARMACOCINÉTICA DEL FACTOR VIII EN SUJETOS CON HEMOFILIA A GRAVE.

Investigador Principal: SANTIAGO BONANAD BOIX

DRP-FAC-2017-01

FACTORES PRONÓSTICO EN EL HEMANGIOMA INFANTIL.

Investigador Principal: JOSÉ LUIS POVEDA ANDRÉS

HUF-HMG-2017-01

CARACTERIZACIÓN FARMACOCINÉTICA DE LA POBLACIÓN CON HEMOFILIA A EN ESPAÑA, UTILIZANDO UNA APLICACIÓN MÉDICA ONLINE BASADA EN UN MODELO POBLACIONAL PUBLICADO Y UN ALGORITMO BAYESIANO.

Investigador Principal: SANTIAGO BONANAD BOIX

STH-OCT-2016-01 . 2019

ESTUDIO FARMACOGENÉTICO DEL TRATAMIENTO EN LA INSUFICIENCIA CARDIACA TERMINAL: INHIBIDORES DE LA ECA, B-BLOQUEANTES Y ANTIALDOSTERÓNICOS.

Investigador Principal: MARÍA JOSÉ HERRERO CERVERA

HLF-ECA-2015-01

Cita

Compartir